Skip to main content

Table 1 General clinical profiles of patients with lupus nephritis at renal biopsy

From: Clinical relevance of glomerular IgM deposition in patients with lupus nephritis

Characteristic

Value

Number of patients

217

Age (mean ± s.d.) (years)

32.7 ± 11.9

Gender (female/male)

182/35

The time between presentation of lupus nephritis and biopsy (median, range) (months)

23 (0–214)

Duration of follow-up (median, range) (months)

49 (6–240)

SLEDAI (mean ± s.d.)

17.5 ± 5.7

Number of fever (non-infectious) (%)

66 (30.4)

Number of eruption (%)

120 (55.3)

Number of photosensitivity (%)

50 (23)

Number of oral ulcer (%)

64 (29.5)

Number of arthralgia (%)

118 (54.4)

Number of neurological disorder (%)

12 (5.5)

Number of anemia (%)

143 (65.9)

Number of thrombocytopenia (%)

66 (30.4)

Number of leukocytopenia (%)

101 (46.5)

Number of hematuria (%)

166 (76.5)

Number of leukocyturia (non-infection) (%)

113 (52.1)

Number of acute renal failure (%)

40 (18.4)

Hemoglobin (mean ± s.d.) (g/L)

101.9 ± 25.8

Urine protein (mean ± s.d.) (g/24 h)

4.3 ± 3.2

Serum creatinine (median, IQR) (μmol/L)

84 (68–129)

C3 (mean ± s.d.) (g/L)

0.46 ± 0.23

C4 (mean ± s.d.) (g/L)

0.23 ± 0.17

Antinuclear antibody positive (%)

214 (98.6)

Anti-dsDNA antibodies positive (%)

152 (70.0)

Anti-Smith antibodies positive (%)

51 (23.5)

Anti-SSA antibodies positive (%)

101 (46.5)

Anti-SSB antibodies positive (%)

24 (11.1)

Anti-C1q antibodies positive (%)

90 (41.5)

  1. s.d. standard deviation, SLEDAI Systemic Lupus Erythematosus Disease Activity Index, IQR interquartile range, dsDNA double-stranded DNA, SSA Sjogren’s syndrome A antigen, SSB Sjogren’s syndrome B antigen